The CCDC88A antibody targets the CCDC88A protein (Coiled-Coil Domain-Containing Protein 88A), also known as HkRP1 or GIV, which is encoded by the CCDC88A gene. This protein is a member of the DExD/H-box helicase family and is characterized by its coiled-coil domains, which mediate protein-protein interactions. CCDC88A plays a role in diverse cellular processes, including cell signaling, migration, and polarity, by acting as a scaffold or adaptor in pathways such as Wnt/β-catenin and G protein-coupled receptor signaling. It has been implicated in cancer progression, neurological disorders, and immune regulation due to its involvement in cytoskeletal reorganization and epithelial-mesenchymal transition (EMT).
Antibodies against CCDC88A are widely used in research to study its expression, localization, and function. They are employed in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect protein levels in tissues or cultured cells. Commercial CCDC88A antibodies are typically raised in hosts such as rabbits or mice, with monoclonal and polyclonal variants available. Researchers often validate these antibodies using knockout controls or siRNA-mediated knockdown to ensure specificity, as cross-reactivity with homologous proteins can occur.
Dysregulation of CCDC88A has been observed in cancers (e.g., colorectal, glioblastoma) and fibrotic diseases, making its antibody a tool for biomarker studies and therapeutic target exploration. However, variability in antibody performance across applications highlights the need for careful validation in experimental settings.